Subscribe
Rasonque launch

Rasonque sales hit $198 million in first five weeks

More than 5,000 patients have been treated since approval, and sales nearly doubled even the most bullish investor estimates.

By Theo Adeyemi, Regulation and biotech correspondent
. 1-minute read.
Package or product image labeled Rasonque daraxonrasib
An image of the Rasonque daraxonrasib product, the drug whose sales are reported in the article. Photograph: Luketheslovak/Wikimedia Commons (CC BY-SA 4.0)

Revolution Medicines' pancreatic cancer drug daraxonrasib, sold as Rasonque, generated $198 million in U.S. sales during its first five weeks after approval, the company said Wednesday evening, according to STAT. The disclosure came as part of the company's third-quarter earnings announcement. The company said more than 5,000 patients have been treated with the pan-RAS inhibitor since the U.S. approval. STAT described the commercial debut as "eye-popping and jaw-dropping".

Chief Commercial Officer Anthony Mancini said on the earnings call, "The U.S. launch of Rasonque is off to a strong start". STAT called that "perhaps the understatement of the year in commercial biotech".

The sales figure was nearly twice the highest projections from investors before the third-quarter earnings report, according to STAT. The publication reported that investors are re-evaluating their forecasts for what lies ahead. STAT noted that while it is still early, the launch could rank among the best cancer drug debuts ever.

Theo AdeyemiRegulation and biotech correspondent

Theo Adeyemi covers drug regulation and the biotech industry for Clinical Observer. He writes from regulators' notices, company filings and published reporting.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.